Planning for a December 2023 U.S. launch for H. pylori, together with the U.S. launch of vonoprazan for Erosive GERD, if approved Adverse event (AE) rates for the vonoprazan-based regimens were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results